Cytokinetics Inc Stock Price, News & Analysis

Cytokinetics (Nasdaq: CYTK) announced on October 29, 2021, the grant of stock options to 8 new employees, totaling 68,550 shares, as a material inducement for their employment. The exercise price for these options is set at $34.91 per share, aligning with the closing stock price on the grant date. Shares will vest over four years, with a quarter vesting after one year and the rest monthly thereafter. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to strengthen the company's workforce.

Cytokinetics (Nasdaq: CYTK) presented preclinical data on CK-3828136 (CK-136) at the 2021 Medicinal Chemistry Gordon Research Conference. CK-136 is a selective cardiac troponin activator aimed at treating conditions like heart failure with reduced ejection fraction (HFrEF). The data shows CK-136 selectively activates the cardiac troponin complex and improves contractility without increasing calcium levels in cardiomyocytes. Its pharmacodynamic properties suggest potential for meaningful clinical benefits, with a favorable pharmacokinetic profile allowing for once or twice daily dosing.

Cytokinetics (Nasdaq: CYTK) announced the upcoming presentation of CK-3828136 (CK-136) data at the 2021 Medicinal Chemistry Gordon Research Conference, scheduled from October 24-29, 2021. The presentation, titled 'The Discovery of CK-136, a Selective Cardiac Troponin Activator,' will occur on October 28, 2021, from 9:45 AM to 10:15 AM Eastern Time, by Dr. Antonio Romero. Cytokinetics continues to focus on developing innovative muscle activators and inhibitors, with ongoing Phase 2 and Phase 3 clinical trials for several candidates, including omecamtiv mecarbil and aficamten.

Cytokinetics (Nasdaq: CYTK) will report its third quarter financial results on November 3, 2021, at 4:00 PM ET, followed by a conference call at 4:30 PM ET. The call is accessible via the company’s website and telephone. Cytokinetics is advancing its drug candidates, including omecamtiv mecarbil, aimed at heart failure, and aficamten for hypertrophic cardiomyopathy. Following positive Phase 3 results, a New Drug Application is planned for omecamtiv mecarbil. A replay of the conference call will be available until November 17, 2021.

Cytokinetics (CYTK) announces its go-to-market strategy for omecamtiv mecarbil and plans for the SEQUOIA-HCM Phase 3 clinical trial of aficamten, anticipated to commence in Q4 2021. The strategy emphasizes understanding heart failure patients, educating cardiologists, ensuring payer access, and supporting patients. SEQUOIA-HCM will enroll 270 patients, assessing the impact of aficamten on peak oxygen uptake and other metrics. The company aims to build a cardiovascular franchise focused on effective communication and efficiency in treating patients with heart failure.

Cytokinetics announced the grant of stock options for 206,300 shares to 14 new employees as a material inducement for their employment, effective September 30, 2021. The options have an exercise price of $35.74, which equals the closing price of the common stock on that date, and will vest over four years. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4). The company is actively pursuing several clinical trials for its muscle-related drug candidates, including omecamtiv mecarbil and aficamten.

Cytokinetics (CYTK) announced its fourth annual Communications Fellowship Grant program, providing a total of $100,000 to support patient advocacy organizations focused on ALS, heart failure, HCM, and SMA. Each of the five selected organizations will receive $20,000. The program aims to enhance communication and outreach efforts in these communities, enabling organizations to implement initiatives that raise awareness and engage audiences. Applications are due by November 12, 2021, with grant recipients announced in January 2022. More details can be found on Cytokinetics' website.

Cytokinetics will host an Analyst and Investor Day on October 7, 2021, from 8:30 AM to 11:30 AM ET at the Westin Grand Central Hotel, New York City. The event will provide updates on commercialization and the cardiovascular pipeline, featuring expert clinicians discussing heart failure challenges. Registration is required by October 6, and the event will also be streamed online. Cytokinetics is advancing treatments for heart failure and hypertrophic cardiomyopathies, with the upcoming U.S. NDA submission for omecamtiv mecarbil following positive Phase 3 trial results.

Cytokinetics announced full results from the REDWOOD-HCM Phase 2 trial evaluating aficamten for hypertrophic cardiomyopathy, showing significant reductions in left ventricular outflow tract gradients and heart failure symptoms. Aficamten demonstrated dose-dependent effects, with 79% of patients reaching treatment goals. Additionally, results from the GALACTIC-HF trial indicated benefits of omecamtiv mecarbil in Black patients, with a 18% trend towards reduced heart failure hospitalization. A Phase 3 trial for aficamten is expected to start by year-end.